China · Delayed Price · Currency is CNY Shanghai Shyndec Pharmaceutical Company Description
Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China.
The company offers 6-APA, potassium clavulanate series, diclofenac sodium extended release tablets, urine-derived biochemical products, nifedipine controlled release tablets, azithromycin, ceftriaxone sodium for injection, methylprednisolone sodium succinate for injection, cefuroxime tablets/capsules, ampicillin acid, penicillin industrial potassium salt, Touboke Yuekui granules/capsules, remifentanil hydrochloride for injection, sodium cefuroxime for injection, ceftriaxone sodium crude salt, D-7ACA, fermented products, milnacipran hydrochloride tablets, compound licorice tablets, 7-ACA, amlodipine besylate tablets, cefoperazone dispersible tablets, and amoxicillin capsules.
Shanghai Shyndec Pharmaceutical Co., Ltd. was founded in 2000 and is headquartered in Shanghai, China.
| Country | China |
| Founded | 2000 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 11,472 |
| CEO | Yong Liu |
Contact Details
Address: No. 378, Jianlu Road Shanghai, 200137 China | |
| Phone | 86 21 6251 0990 |
| Website | shyndec.com |
Stock Details
| Ticker Symbol | 600420 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE000001JG2 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Yong Liu | President and Director |
| Zhongxi Zhang | Vice President and Board Secretary |
| Xiangchen Wang | Chief Financial Officer |
| Lei Gao | Accounting Supervisor |